Conceptual Framework of A Next-generation General-purpose Clinical Scientific Disease Database

PENG Min; CHEN Qianru; CHEN Kai

doi:10.3971/j.issn.1000-8578.2024.23.1224

Cancer Research on Prevention and Treatment > 2024 > 51(5): 321-327. > DOI: 10.3971/j.issn.1000-8578.2024.23.1224

PENG Min, CHEN Qianru, CHEN Kai. Conceptual Framework of A Next-generation General-purpose Clinical Scientific Disease Database[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 321-327. DOI: 10.3971/j.issn.1000-8578.2024.23.1224

Citation:

PDF (1619 KB)

Conceptual Framework of A Next-generation General-purpose Clinical Scientific Disease Database

PENG Min^{1, 2,},
CHEN Qianru^{1, 3},
CHEN Kai^{1, 3, 4, , ,}

1.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
2.
Disease Registry Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
3.
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
4.
Artificial Intelligence Lab, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Funding: National Natural Science Foundation of China (No. 82271650); Guangdong Development and Reform Commission (No. 4250022021); Guangzhou Science Technology and Innovation Commission (Nos. 202102010221, 20212200003); National Institute of Hospital Administration, National Health Commission of the People’s Republic of China (No. RXDBZ-2022-04); Yat-sen Management Program of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (No. GL2307)

More Information

Corresponding author:
CHEN Kai, E-mail: chenkai23@mail.sysu.edu.cn
Received Date: November 22, 2023
Revised Date: January 17, 2024
Available Online: August 07, 2024

Graphical Abstract

Abstract

Abstract

Empowered by the rapid development of artificial intelligence technology and information security technology, basic medicine, translational medicine, and clinical medicine have entered a new era. In this process, the relevant data such as text, genetics, images, and videos have increased at an astonishing rate. Traditional specialized disease databases cannot adapt to the multimodality of data and the multicentralization of data sources in the present/future. Therefore, establishing a next-generation multimodal and multicenter collaborative specialized disease database that is suitable for secure data sharing and ethical in clinical research is essential. This paper expounds the concept and basic framework of developing a next-generation clinical research disease database with universal use, emphasizing the establishment of a multimodal data integration mechanism, a multicenter collaborative system supported by privacy-preserving computing, highly intelligent software and hardware entities, and an integrated operational management mode. It also introduces the application of this concept in the construction of a breast cancer three-dimensional life database, a project of China Breast Cancer Innovation Alliance.
- Specialized disease data,
- Data management,
- Clinical research database,
- Database construction,
- Breast cancer

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (20)

References

[1]	SEER. Cancer Stat Facts: Female Breast Cancer[DB/OL]. 2023. https://seer.cancer.gov/statfacts/html/breast.html.
[2]	Cancer Research UK. Breast cancer statistics(2016-2020)[DB/OL]. 2023. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Three.
[3]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108
[4]	Liu Z, Shi M, Ren Y, et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy[J]. Mol Cancer, 2023, 22(1): 35. doi: 10.1186/s12943-023-01738-6
[5]	Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy[J]. Curr Oncol, 2022, 29(5): 3044-3060. doi: 10.3390/curroncol29050247
[6]	Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support[J]. J Biomed Inform, 2009, 42(2): 377-381. doi: 10.1016/j.jbi.2008.08.010
[7]	Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners[J]. J Biomed Inform, 2019, 95: 103208. doi: 10.1016/j.jbi.2019.103208
[8]	Ouyang Q, Li S, Gao M, et al. Risk factors associated with loss to follow-up of breast cancer patients: A retrospective analysis[J]. Breast, 2021, 57: 36-42. doi: 10.1016/j.breast.2021.02.012
[9]	Yang Y, Liu J, Peng M, et al. Introduction of a multicenter online database for non-metastatic breast cancer in China[J]. Sci China Life Sci, 2020, 63(9): 1417-1420. doi: 10.1007/s11427-019-1625-1
[10]	Chen K, Li H, Pan Z, et al. Insights into artificial Intelligence in clinical oncology: opportunities and challenges[J]. Sci China Life Sci, 2022, 65(3): 643-647.
[11]	Mustachio LM, Roszik J. Single-Cell Sequencing: Current Applications in Precision Onco-Genomics and Cancer Therapeutics[J]. Cancers (Basel), 2022, 14(3): 657. doi: 10.3390/cancers14030657
[12]	江杨, 于惠芝, 高亚, 等. AI细胞形态学联合DNA定量分析鉴别良恶性胸腹水的探讨[J]. 肿瘤防治研究, 2023, 50(4): 390-396. [Jiang Y, Yu HZ, Gao Y, et al. AI Cytomorphology Combined with DNA-image Cytometry for Identifying Benign and Malignant Pleural Effusion and Ascites[J]. Zhong Liu Fang Zhi Yan Jiu, 2023, 50(4): 390-396.] Jiang Y, Yu HZ, Gao Y, et al. AI Cytomorphology Combined with DNA-image Cytometry for Identifying Benign and Malignant Pleural Effusion and Ascites[J]. Zhong Liu Fang Zhi Yan Jiu, 2023, 50(4): 390-396.
[13]	陈可, 王俊. 中晚期非小细胞肺癌专病数据库的构建及应用探讨[J]. 中国数字医学, 2022, 17(6): 109-113. [Chen K, Wang J. Construction and application of the special disease database for middle-advanced non-small cell lung cancer[J]. Zhongguo Shu Zi Yi Xue, 2022, 17(6): 109-113.] Chen K, Wang J. Construction and application of the special disease database for middle-advanced non-small cell lung cancer[J]. Zhongguo Shu Zi Yi Xue, 2022, 17(6): 109-113.
[14]	陈嘉旖, 陶蓉. 基于临床大数据的肺癌专病数据库建设[J]. 中国数字医学, 2021, 16(11): 39-42. [Chen JY, Tao R. Construction of the Special Disease Database of Lung Cancer Based on Clinical Big Data[J]. Zhongguo Shu Zi Yi Xue, 2021, 16(11): 39-42.] Chen JY, Tao R. Construction of the Special Disease Database of Lung Cancer Based on Clinical Big Data[J]. Zhongguo Shu Zi Yi Xue, 2021, 16(11): 39-42.
[15]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[16]	张宇. 《数据安全法》中规定的法律义务[J]. 中国信息化, 2023(10): 36-38. [Zhang Y. Legal Obligations under the Data Security Law of China[J]. Zhongguo Xin Xi Hua, 2023(10): 36-38.] Zhang Y. Legal Obligations under the Data Security Law of China[J]. Zhongguo Xin Xi Hua, 2023(10): 36-38.
[17]	何志鹏, 朱志远. 国家安全法体系的边界[J]. 山东大学学报(哲学社会科学版), 2023, (6): 118-128. [He ZP, Zhu ZY. The Boundary of the National Security Legal System[J]. Shandong Da Xue Xue Bao (Zhe Xue She Hui Ke Xue Ban), 2023, (6): 118-128.] He ZP, Zhu ZY. The Boundary of the National Security Legal System[J]. Shandong Da Xue Xue Bao (Zhe Xue She Hui Ke Xue Ban), 2023, (6): 118-128.
[18]	国家卫生健康委员会. “十四五”全民健康信息化规划[DB/OL]. 2022. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=49eb570ca79a42f688f9efac42e3c0f1. [National Health Commission of the People’S Republic of China. The 14th Five-Year Plan for National Health Informatization[DB/OL]. 2022. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=49eb570ca79a42f688f9efac42e3c0f1.] National Health Commission of the People’S Republic of China. The 14th Five-Year Plan for National Health Informatization[DB/OL]. 2022. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=49eb570ca79a42f688f9efac42e3c0f1.
[19]	中国临床肿瘤学会. 乳腺癌临床科研标准数据集: T/CSCO 2—2022[S/OL]. 2022. [Chinese Society of Clinical Oncology. Standard Datasets for Breast Cancer Clinical Scientific Research: T/CSCO 2—2022[S/OL]. 2022.] Chinese Society of Clinical Oncology. Standard Datasets for Breast Cancer Clinical Scientific Research: T/CSCO 2—2022[S/OL]. 2022.
[20]	中国临床肿瘤学会. 乳腺癌名词术语: T/CSCO 1—2022[S/OL]. 2022. https://www.ttbz.org.cn/Pdfs/Index/?ftype=st&pms=66386. [Chinese Society of Clinical Oncology. Terminology of Breast Cancer: T/CSCO 1—2022[S/OL]. 2022. https://www.ttbz.org.cn/Pdfs/Index/?ftype=st&pms=66386.] Chinese Society of Clinical Oncology. Terminology of Breast Cancer: T/CSCO 1—2022[S/OL]. 2022. https://www.ttbz.org.cn/Pdfs/Index/?ftype=st&pms=66386.

Cited By

Cited by

Periodical cited type(4)

1.	胡婉彦，汪溢，秦晓燕，郑志昂. 膀胱移行细胞癌患者血cGAS、STING基因表达与癌组织CD44阳性的剂量—效应关系. 疑难病杂志. 2025(02): 214-219 .
2.	耿改丽，连文晓，陈蕊. 个案护理对膀胱肿瘤患者自我护理能力和生命质量的影响. 齐鲁护理杂志. 2024(01): 41-44 .
3.	韦兴发，李智强，陈从其，林云侨，陈锦添. 卡介苗灌注联合经尿道红激光汽化切除术治疗非肌层浸润性膀胱癌的效果. 国际泌尿系统杂志. 2024(04): 628-631 .
4.	郑宏，王栋洋. 膀胱癌组织中miR-451表达及其对患者术后生存预后的预测价值分析. 国际泌尿系统杂志. 2024(06): 1024-1027 .

Other cited types(1)

Figures(1)

Get Citation

PDF

XML

Article views (2439) PDF downloads (1474) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Conceptual Framework of A Next-generation General-purpose Clinical Scientific Disease Database